m6A-centered Crosstalk Information

Mechanism of Crosstalk between m6A Modification and Epigenetic Regulation
Crosstalk ID
M6ACROT05265
 [1]
Non-coding RNA CircPDE5A WTAP  lncRNA       miRNA   circRNA Direct Inhibition m6A modification EIF3C EIF3C WTAP Methylation : m6A sites
m6A Modification:
m6A Regulator Wilms tumor 1-associating protein (WTAP) WRITER
 Regulator Info 
m6A Target Eukaryotic translation initiation factor 3 subunit C (EIF3C)
 Targert Gene 
Epigenetic Regulation that have Cross-talk with This m6A Modification:
Epigenetic Regulation Type Non-coding RNA (ncRNA)
Epigenetic Regulator Circ_PDE5A circRNA View Details
Regulated Target Pre-mRNA-splicing regulator WTAP (WTAP) View Details
Crosstalk Relationship ncRNA  →  m6A Inhibition
Crosstalk Mechanism ncRNAs directly impacts m6A modification through recruiting m6A regulator
Crosstalk Summary Circ_PDE5A blocks the WTAP-dependent N6-methyladenisine (m6A) methylation of Eukaryotic translation initiation factor 3 subunit C (EIF3C) mRNA by forming the circPDE5A-WTAP complex, and finally disrupts the translation of EIF3C. Moreover, the circPDE5A-dependent decrease in EIF3C expression inactivates the MAPK pathway and then restrains PCa progression.
Responsed Disease Prostate cancer ICD-11: 2C82
 Disease Info 
In-vivo Model 2 × 106 stably transfected 22Rv-1 cells were injected via the tail vein into BALB/c nude mice. After 8 weeks, tumor metastasis loci were measured via in vivo imaging system (IVIS). After 8 weeks, the mice were euthanized, the lungs were surgically dissected and embedded in paraffin. Then, the specimens were stained with hematoxylin and eosin.
Full List of Potential Compound(s) Related to This m6A-centered Crosstalk
2C82: Prostate cancer 1 Compound(s) Regulating the Disease Click to Show/Hide the Full List
 Compound Name CC-94676 Phase 1 [2]
External Link
TTD: DNY63Z
References
Ref 1 circPDE5A regulates prostate cancer metastasis via controlling WTAP-dependent N6-methyladenisine methylation of EIF3C mRNA. J Exp Clin Cancer Res. 2022 Jun 2;41(1):187. doi: 10.1186/s13046-022-02391-5.
Ref 2 ClinicalTrials.gov (NCT04428788) Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CC-94676 in Subjects With Metastatic Castration-Resistant Prostate Cancer. U.S. National Institutes of Health.